Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 1
2002 1
2003 1
2004 2
2005 3
2006 4
2007 2
2008 2
2009 2
2010 1
2011 2
2012 3
2013 1
2014 2
2015 3
2016 2
2017 3
2018 6
2019 2
2020 1
2021 4
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy.
Fessel J. Fessel J. Alzheimers Dement (N Y). 2022 Feb 1;8(1):e12242. doi: 10.1002/trc2.12242. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35128031 Free PMC article.
Evidence is also presented that clemastine, fingolimod, and rolipram, benefit both myelination and synaptogenesis. It is suggested that a regimen that includes one of them plus an anti-amyloid drug, could reverse AD....
Evidence is also presented that clemastine, fingolimod, and rolipram, benefit both myelination and synaptogenesis. It is suggested th …
Phosphodiesterase inhibitors say NO to Alzheimer's disease.
Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M, Tewari D, Argüelles S, Mehrzadi S, Hosseinzadeh A, D'onofrio G, Orhan IE, Sureda A, Xu S, Momtaz S, Farzaei MH. Nabavi SM, et al. Food Chem Toxicol. 2019 Dec;134:110822. doi: 10.1016/j.fct.2019.110822. Epub 2019 Sep 16. Food Chem Toxicol. 2019. PMID: 31536753 Review.
PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive …
PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular …
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Hu J, Pan T, An B, Li Z, Li X, Huang L. Hu J, et al. Eur J Med Chem. 2019 Feb 1;163:512-526. doi: 10.1016/j.ejmech.2018.12.013. Epub 2018 Dec 7. Eur J Med Chem. 2019. PMID: 30553143
Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics, we have designed, synthesized and evaluated a series of new clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands …
Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics …
Synaptic proteasome is inhibited in Alzheimer's disease models and associates with memory impairment in mice.
Ribeiro FC, Cozachenco D, Heimfarth L, Fortuna JTS, de Freitas GB, de Sousa JM, Alves-Leon SV, Leite REP, Suemoto CK, Grinberg LT, De Felice FG, Lourenco MV, Ferreira ST. Ribeiro FC, et al. Commun Biol. 2023 Nov 7;6(1):1127. doi: 10.1038/s42003-023-05511-9. Commun Biol. 2023. PMID: 37935829 Free PMC article.
Here, we investigate proteasome function and localization at synapses in Alzheimer's disease (AD) post-mortem brain tissue and in experimental models. ...Reduced synaptic proteasome activity instigated by AbetaOs is corrected by treatment with rolipram
Here, we investigate proteasome function and localization at synapses in Alzheimer's disease (AD) post-mortem brain tis …
4-(3-Cyclopentoxy-4-[11C]methoxy-phenyl)pyrrolidin-2-one.
Leung K. Leung K. 2006 Jan 12 [updated 2008 Jan 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2006 Jan 12 [updated 2008 Jan 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641301 Free Books & Documents. Review.
PDE4 inhibitors have been studied in the treatment of neuropsychiatric disorders (depression and dementia of Alzheimer's disease) (5-7) and inflammatory diseases (asthma) (8, 9). ...At least one study using positron emission tomography (PET) to study R-[(11)C …
PDE4 inhibitors have been studied in the treatment of neuropsychiatric disorders (depression and dementia of Alzheimer's di
Phosphodiesterases as therapeutic targets for Alzheimer's disease.
García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. García-Osta A, et al. ACS Chem Neurosci. 2012 Nov 21;3(11):832-44. doi: 10.1021/cn3000907. Epub 2012 Oct 1. ACS Chem Neurosci. 2012. PMID: 23173065 Free PMC article. Review.
Alzheimer's disease (AD) is the most common form of dementia among the elderly. ...Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compound found to effe
Alzheimer's disease (AD) is the most common form of dementia among the elderly. ...Promising non-amyloid related candid
Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling.
Cong YF, Liu FW, Xu L, Song SS, Shen XR, Liu D, Hou XQ, Zhang HT. Cong YF, et al. Int J Neuropsychopharmacol. 2023 Sep 25;26(9):585-598. doi: 10.1093/ijnp/pyad042. Int J Neuropsychopharmacol. 2023. PMID: 37490542 Free PMC article.
BACKGROUND: Alzheimer disease (AD) and depression often cooccur, and inhibition of phosphodiesterase-4 (PDE4) has been shown to ameliorate neurodegenerative illness. ...Neurochemical measures were conducted to explore the underlying mechanism of rolipram. RES …
BACKGROUND: Alzheimer disease (AD) and depression often cooccur, and inhibition of phosphodiesterase-4 (PDE4) has been shown t …
A Timeline of Ca2+/cAMP Signalling: From Basic Research to Potential Therapeutics for Dementia.
Bergantin LB. Bergantin LB. Curr Alzheimer Res. 2022;19(3):179-187. doi: 10.2174/1567205019666220415125447. Curr Alzheimer Res. 2022. PMID: 35430979
RESULTS: Then, combined with improvements in the lifestyle issues, these novel therapeutics may allow sustained improvements in the life quality of age-related neurological patients. CONCLUSIONS: In addition, considering coronavirus disease 2019 (COVID-19) is a rapidly evo …
RESULTS: Then, combined with improvements in the lifestyle issues, these novel therapeutics may allow sustained improvements in the life qua …
Effects of zaprinast and rolipram on olfactory and visual memory in the social transmission of food preference and novel object recognition tests in mice.
Akar F, Mutlu O, Celikyurt IK, Bektas E, Tanyeri MH, Ulak G, Tanyeri P, Erden F. Akar F, et al. Drug Target Insights. 2014 Apr 29;8:23-9. doi: 10.4137/DTI.S14813. eCollection 2014. Drug Target Insights. 2014. PMID: 24855335 Free PMC article.
There was no significant effect of zaprinast and rolipram on total distance moved, speed, and center zone duration in open field test. Results of this study revealed that both zaprinast and rolipram enhanced visual memory in NOR test, however zaprinast exerted a sig …
There was no significant effect of zaprinast and rolipram on total distance moved, speed, and center zone duration in open field test …
Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.
Akar F, Mutlu O, Komsuoglu Celikyurt I, Ulak G, Erden F, Bektas E, Tanyeri P. Akar F, et al. Med Sci Monit Basic Res. 2014 Jul 24;20:105-11. doi: 10.12659/MSMBR.891149. Med Sci Monit Basic Res. 2014. PMID: 25057848 Free PMC article.
BACKGROUND: Phosphodiesterase (PDE) inhibitors in the central nervous system have been shown to stimulate neuronal functions and increase neurogenesis in Alzheimer disease (AD) patients. MATERIAL/METHODS: The aim of this study was to investigate the effects of zapri …
BACKGROUND: Phosphodiesterase (PDE) inhibitors in the central nervous system have been shown to stimulate neuronal functions and increase ne …
48 results